FINVASIA-GROUP
Finvasia today announced that it has appointed Tajinder Virk as the interim Chief Executive Officer for ZuluTrade. He will replace the previous CEO from the company, effective immediately.
"Tajinder has been instrumental in building upon Finvaisa’s success and has an impressive track record in delivering growth for our group companies," said Sarvjeet Singh Virk, CMD & Co-founder Finvasia. "We have seen Tajinder (A.K.A. Natty) in action first hand and have the utmost confidence that his deep financial experience and leadership skills will drive results and accelerate ZuluTrade’s business in this interim role."
Tajinder Virk is the CEO of Finvasia Group of companies and is an exceptional leader with deep familiarity with all aspects of the business that allows him to develop and lead the execution of the group’s strategic vision, assess risks and guide the group’s growth. He has worked with some of the largest investment banks and hedge funds on Wall Street and has managed multibillion-dollar funds for major US banks, before co-founding Finvasia. At ZuluTrade, Tajinder will work closely with the team to deliver on the business expansion plan.
Commenting on the appointment, Tajinder said, “Finvasia is known for its innovative business approach and for its ability to create value for its clients. We see ZuluTrade as the largest Social Wealth Management platform that will bring more asset classes and industry participants together under a single platform.
“ZuluTrade is among the largest and the original social trading platforms that revolutionised copy trading in 2008. ZuluTrade 2.0 will maintain its legacy of being broker neutral, so it has no conflict of interest with its investors. We will be offering a variety of asset classes, encouraging more investors, leaders and brokers to join the platform whilst creating a conducive environment for them to grow their wealth,” he continued.
Finvasia’s board has simultaneously commenced a formal search for a permanent CEO for ZuluTrade who can deliver on the Group’s expectations for future ready products while maintaining its core values and cultures.
About ZULUTRADE (https://www.zulutrade.com )
ZuluTrade is the original social trading platform that revolutionised copy trading in 2008. It offers a massive database of Algo signals and strategies currently available across the market, catering to both advanced and novice investors alike.
It's a broker neutral platform that has catered to over 2.5 million clients in over 100 countries and supports over twenty-six languages.
About FINVASIA (https://finvasia.com )
Finvasia is a multi-disciplinary, multinational organisation that owns and operates over a dozen brands across financial services, technology, real estate and healthcare verticals.
Finvasia Group has managed funds for some of the notable hedge funds of Wall street, launched the first and only commission free ecosystem for financial products in India and is now aggressively expanding its presence in the European market. The Group has provided technology to some of the notable listed and unlisted financial services entities across the globe.
Furthermore, its healthcare division recently launched a medically proven diabetes reversal program in India and has engaged scientists from various specialised fields in an effort to build nano and micro medical devices that will cater to the future of medical engineering.
In the last 13 years, Finvasia has catered to a few million clients in over 180 countries directly or via its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005251/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom